Human medicines for which an application for registration has been submitted as contemplated in Section 15 of the Act,
| (a) | In respect of the submission of an application for registration of— |
| (i) | Products submitted with clinical and or toxicological data (first strength, first dosage form): R13 640 per application; |
| (ii) | Strengths and dosage forms other than those referred to in subparagraph (i): R4 290 per application; |
| (iii) | Products submitted with no clinical or toxicology data (first strength, first dosage form): R6 050 per application; |
| (iv) | Strengths and dosage forms other than those referred to in subparagraph (iii): R1 980; |
| (v) | Screening fee on receipt of an application: R1 760; |
| (vi) | Evaluation of additional submitted clinical data (pre-registration): R2 750; |
| (vii) | An application in terms of Section 15C of the Act: R33 000; |
| (b) | Any medicine, the registration of which has been approved by the Authority in terms of Section 15(3) of the Act: |
| (i) | In respect of registration of any medicine, the registration of which has been approved by the Authority in terms of Section 15(3) of the Act and in respect of which an application fee has been paid: R1 760 for each registration; |
| (ii) | Evaluation of request for rescheduling of products: R5 500; |
| (iii) | Evaluation of request to amend Professional Information in respect of which clinical data relating to safety and efficacy must be evaluated (post- registration): R3 300; |
| (iv) | Annually, in respect of the retention of the registration of a medicine, the registration of which has been approved by the Authority in terms of Section 15(3): R1 700: Provided that this provision shall come into effect one year after the date on which the registration of the said medicine was approved by the Authority in terms of Section 15(3): Provided further that the said fees payable during a particular calendar year shall be payable on or before the last working day of June that year, failing which the registration may be cancelled in terms of Section 16(4). |
